- Home
- DYN
as 06-27-2025 11:31am EST
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.4B | IPO Year: | 2020 |
| Target Price: | $43.60 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.36 - $47.45 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kerr Douglas | DYN | Chief Medical Officer | Jun 5 '25 | Sell | $13.35 | 1,342 | $17,915.70 | 92,815 | |
| Cox John | DYN | CEO & President | Jun 5 '25 | Sell | $13.35 | 4,060 | $54,201.00 | 142,179 | |
| Friedl-Naderer Johanna | DYN | Chief Commercial Officer | Jun 5 '25 | Sell | $13.35 | 146 | $1,949.10 | 95,911 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
JonesTrading Initiates Coverage on Dyne Therapeutics With Buy Rating, $30 Price Target
Insider Monkey
3 days ago
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101
MT Newswires
3 days ago
Bernstein Initiates Dyne Therapeutics at Market Perform With $13 Price Target
TipRanks
9 days ago
Dyne at ‘attractive entry point’ following pullback, says Chardan
MT Newswires
10 days ago
Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy
GlobeNewswire
10 days ago
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
GlobeNewswire
11 days ago
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
GlobeNewswire
22 days ago
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.